Home / Business and Economy / Psychedelic Firm Sued for Trade Secret Theft
Psychedelic Firm Sued for Trade Secret Theft
3 Feb
Summary
- Signant Health claims Definium stole trade secrets for LSD trials.
- Definium allegedly shared confidential data with rival EMA Wellness.
- Lawsuit seeks monetary damages and injunction against trade secret misuse.
Signant Health filed a lawsuit on February 2, 2026, accusing Definium Therapeutics of stealing trade secrets. The legal action alleges that Definium improperly shared confidential information related to its clinical trials for an LSD therapy with a rival company, EMA Wellness.
Definium, formerly known as MindMed, is developing an LSD treatment for severe depression and anxiety. Signant Health assisted Definium with its Phase 2 trials starting in 2021. The lawsuit claims that Todd Solomon, an executive at Definium, holds a stake in EMA Wellness and secretly ensured EMA's selection for Phase 3 trials.
According to the lawsuit, Definium and Solomon aided EMA in replicating Signant's clinical trial platform by sharing proprietary data. Signant is seeking monetary damages and a court order to halt the misuse of its trade secrets.
